Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

9.330 +0.850 (+10.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Psychedelic Stock Gainers And Losers From March 21, 2023
 
Via Benzinga
EXCLUSIVE: NYC Ketamine Center Co-Founder On Prices, Insurance, Competition & Expansion
This is the third article of a three-part series, you can find the first and 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 20, 2023
 
Via Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
The "Rags-To-Riches" Portfolio: An Update
Cannabis, psychedelic, and plant-based food stocks performed extremely poorly in 2022, down 73% vs. 2021 but perhaps some of them will bounce back with major returns in 2023. 
Via Talk Markets
Where Compass Pathways Stands With Analysts
 
Via Benzinga
Earnings Preview: Compass Pathways
 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 17, 2023
 
Via Benzinga
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
 
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
 
Via Benzinga
COMPASS Pathways: New Data & Insight On Psilocybin Therapy For Treatment-Resistant Depression
COMPASS Pathways' (NASDAQ: CMPS) Phase 2b study of synthetic psilocybin COMP360 paired with psychological support for Treatment-Resistant Depression (TR 
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
 
Via Benzinga
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today
 
Via Benzinga
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 9, 2023
 
Via Benzinga
Numinus Wellness, Seelos Therapeutics Among Top Psychedelic Movers Of Today
 
Via Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
Compass Pathways - Entering A Brave New World
A look at what Compass Pathways is focused on, its clinical trial progress to date, its latest quarterly financials, the history of its stock price performance, and the price forecasts for the stock... 
Via Talk Markets
Psychedelic Stock Gainers And Losers From March 6, 2023
 
Via Benzinga
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.   
Via Benzinga
2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull Market
Investing now is an admittedly risky bet, but the payoff could be massive. 
Via The Motley Fool
2 Growth Stocks With Incredible Potential in the Next 5 Years
Neither is profitable, but both could be on the verge of massive booms in revenue. 
Via The Motley Fool
Cybin, GH Research Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From March 2, 2023
 
Via Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From February 28, 2023
 
Via Benzinga
COMPASS Pathways Shares Q4 & Year-End 2022 Financials, Advances Phase 3 Psilocybin Trials
Mental healthcare biotech COMPASS Pathways (NASDAQ: CMPS) reported its financial results for the fourth quarter and year-end 2022 and provided an update on recent pipeline and business progress.... 
Via Benzinga
Compass Pathways Plc (CMPS) Q4 2022 Earnings Call Transcript
CMPS earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Psychedelic Stock Gainers And Losers From February 27, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.